Design and reshaping of an scFv directed against human platelet glycoprotein VI with diagnostic potential.

Blood platelets play a key role in physiological hemostasis and in thrombosis. As a consequence, platelet functional analysis is widely used in the diagnosis of hemorrhagic disorders as well as in the evaluation of thrombosis risks and of the efficacy of antithrombotics. Glycoprotein (GP) VI is a platelet-specific collagen-signaling receptor.

Design and humanization of a murine scFv that blocks human platelet glycoprotein VI in vitro.

Platelet adhesion and aggregation at the site of vascular injury is essential for hemostasis, but can also lead to arterial occlusion in thrombotic disorders. Glycoprotein (GP) VI is the major platelet membrane receptor that interacts directly with collagen, the most thrombogenic compound in the blood vessels. GPVI could therefore be a major therapeutic target.

Absence of collagen-induced platelet activation caused by compound heterozygous GPVI mutations.

The glycoprotein VI (GPVI)/FcRgamma complex is a key receptor for platelet activation by collagen. We describe, for the first time, 2 genetic abnormalities in one patient. This 10-year-old girl presented ecchymoses since infancy, a prolonged bleeding time despite a normal platelet count and no antiplatelet antibodies.

Embryonic erythroid cells transformed by avian erythroblastosis virus may proliferate and differentiate.

Embryonic chick cells from the primitive streak stage to later stages of the developing embryo were infected with avian erythroblastosis virus (AEV). The data indicate that the greatest number of target cells for AEV was observed in the 12-somite blastoderm and gradually decreased in hemopoietic tissues with the development of the embryo. The target cell for AEV is not in the BFU-E compartment, as it is in the adult bone marrow, but is probably recruited within the CFU-M compartment which precedes the BFU-E compartment.

A factor present in normal mouse serum stimulates late erythroid precursor proliferation.

A factor present in normal mouse serum stimulates proliferation of late erythroid precursors grown in cultures in vitro. This factor was shown not to have a corrective effect on culture conditions by the following criteria: (a) CFU-E frequency in the absence of NMS was at least as great as published data for various mouse strains, (b) an inhibitory effect of endotoxin was ruled out, (c) sensitivity of erythroid precursors to erythropoietin was similar in the presence or absence of NMS, and (d) the number of colonies was linearly related to the cell dose. The enhancing effect of NMS was independent of hemin, transferrin, or dexamethasone, products all known to be stimulators of erythropoiesis.